VISTERRA, INC.
acquired by Otsuka4 known investors
Find your way into VISTERRA, INC.
1,074 people in our graph share verified history with the VISTERRA, INC. team — schools, employers, funds. One of them is your warm intro.
Issi Rozenunlockedknows Karthik Viswanathan · together at Massachusetts Institute of Technology (overlapped)
×7knows the team · via Massachusetts Institute of Technology
×4knows the team · via Stanford University Graduate School of Business
A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
Founders & leadership
ZS
Zachary ShriverPresident and Chief Executive Officer
KV
Karthik ViswanathaninVice President, ResearchFounding scientist and Vice President of Research at Visterra, Inc., a spin-out from MIT that was acquired by Otsuka in 2018, with expertise in monoclonal antibodies, protein engineering, and computational biology platforms for therapeutic development.
Investors · 4
Founder mafia
2 people who came through VISTERRA, INC. went on to found or lead other companies.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does VISTERRA, INC. do?
- A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
- Who are VISTERRA, INC.'s investors?
- VISTERRA, INC.'s investors include CTI Life Sciences Fund L.P., Cycad Group LLC, Lux Capital, MRL Ventures Fund.
- Who acquired VISTERRA, INC.?
- VISTERRA, INC. was acquired by Otsuka.